<DOC>
	<DOCNO>NCT00889525</DOCNO>
	<brief_summary>This study design check efficacy new oral medical drug treatment , namely Cabergoline , treatment Cushing Disease due pituitary adenoma . Background : Cabergoline Dopamine 2 receptor agonist . Corticotroph adenoma show D2 receptor vitro study .</brief_summary>
	<brief_title>Study Cabergoline Treatment Corticotroph Pituitary Tumor</brief_title>
	<detailed_description />
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Patient Cushing 's disease uncured biochemically pituitary surgery adenoma histopathology Patient 's intolerance drug know sensitivity ergot derivative Pregnancy , lactation female wish pregnant Any serious medical illness Patient drug know interaction cabergoline include antihypertensive like reserpine methyl dopa , neuroleptic , metoclopramide , etc</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Cabergoline</keyword>
</DOC>